tradingkey.logo
搜索

IDEAYA Biosciences Inc

IDYA
添加自选
38.200USD
-0.410-1.06%
交易中 09/18, 13:30美东
3.68B总市值
亏损市盈率 TTM

关于 IDEAYA Biosciences Inc 公司

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

IDEAYA Biosciences Inc 简介

公司代码IDYA
公司名称IDEAYA Biosciences Inc
上市日期May 23, 2019
CEOHata (Yujiro S)
员工数量131
证券类型Ordinary Share
年结日May 23
公司地址7000 Shoreline Ct, Suite 350
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94080
电话16504436209
网址https://www.ideayabio.com/
公司代码IDYA
上市日期May 23, 2019
CEOHata (Yujiro S)

IDEAYA Biosciences Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott William Morrison, CPA
Mr. Scott William Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Douglas B. (Doug) Snyder
Mr. Douglas B. (Doug) Snyder
Chief Legal Officer
Chief Legal Officer
2.08K
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--

常见问题

IDEAYA Biosciences Inc的前五大股东是谁?

IDEAYA Biosciences Inc 的前五大股东如下:Mr. Douglas B. (Doug) Snyder

有多少机构持有IDEAYA Biosciences Inc(IDYA)的股份?

截至2026Q1,共有518家机构持有IDEAYA Biosciences Inc的股份,合计持有的股份价值约为97.55M,占公司总股份的111.03%。与2025Q4相比,机构持股有所增加,增幅为-12932948.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有